<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7603620\results\search\disease\results.xml">
  <result pre="tissue activities and levels of oxidative stress markers while improving" exact="cardiovascular disease" post="risk indices and DOX-induced histopathological lesions. The in vitro"/>
  <result pre="action of topoisomerase II during normal DNA replication needed for" exact="cancer" post="cell division and growth [2â€&quot;5]. Doxorubicin is often used"/>
  <result pre="of solid and blood cancers such as breast and ovarian," exact="leukemia" post="(acute myelogenous leukemia (AML) and acute lymphoblastic leukemia), Hodgkin"/>
  <result pre="blood cancers such as breast and ovarian, leukemia (acute myelogenous" exact="leukemia" post="(AML) and acute lymphoblastic leukemia), Hodgkin lymphoma, non-Hodgkin lymphoma,"/>
  <result pre="lymphoblastic leukemia), Hodgkin lymphoma, non-Hodgkin lymphoma, Wilm's tumor, neuroblastoma, and" exact="sarcoma" post="[6â€&quot;8]. For example, for breast cancer management, doxorubicin is"/>
  <result pre="lymphoma, Wilm's tumor, neuroblastoma, and sarcoma [6â€&quot;8]. For example, for" exact="breast cancer" post="management, doxorubicin is typically combined and given with cyclophosphamide;"/>
  <result pre="Wilm's tumor, neuroblastoma, and sarcoma [6â€&quot;8]. For example, for breast" exact="cancer" post="management, doxorubicin is typically combined and given with cyclophosphamide;"/>
  <result pre="13], while its occasional side effects include hyperuricemia, heart failure," exact="pericardial effusion," post="cardiomyopathy, conjunctivitis, and skin rashes [14, 15]. Of these"/>
  <result pre="rashes [14, 15]. Of these side effects, cumulative and dose-related" exact="cardiomyopathy" post="and heart failure are of grave concerns to cancer"/>
  <result pre="dose-related cardiomyopathy and heart failure are of grave concerns to" exact="cancer" post="patients and managing physicians alike, thus, limiting its clinical"/>
  <result pre="proposed DOX-mediated cardiotoxicity mechanisms, leading to oxidative stress that causes" exact="cardiomyopathy" post="[53]. Oxidative stress has been reported to increase lipid"/>
  <result pre="increased serum cholesterol, triglyceride, LDL-c, and FFAs) [59â€&quot;64] and increases" exact="cardiovascular disease" post="risk [65]. This hyperlipidemia is thought to be mediated"/>
  <result pre="resulting in glucose and fatty acid transporters expression and causing" exact="hyperglycemia" post="and hyperlipidemia [65]. Irvingia gabonensis seeds have been reported"/>
  <result pre="have been reported to induce weight loss, antihyperlipidemia, and reduced" exact="cardiovascular disease" post="risk factors in both animal [59â€&quot;64] and human studies"/>
  <result pre="11ZhaoM.DingX.-F.ShenJ.-Y.ZhangX. P.DingX. W.XuB.Use of liposomal doxorubicin for adjuvant chemotherapy of" exact="breast cancer" post="in clinical practiceJournal of Zhejiang University. Science. B2017181152610.1631/jzus.B160030328070993 12MagniM.BianconG.RizzitanoS.et"/>
  <result pre="P.DingX. W.XuB.Use of liposomal doxorubicin for adjuvant chemotherapy of breast" exact="cancer" post="in clinical practiceJournal of Zhejiang University. Science. B2017181152610.1631/jzus.B160030328070993 12MagniM.BianconG.RizzitanoS.et"/>
  <result pre="II differently modulate the toxicity of anthracyclines in cardiac and" exact="cancer" post="cellsPLoS One2013810, article e7667610.1371/journal.pone.007667624116135 29DengS.YanT.JendrnyC.et al.Dexrazoxane may prevent doxorubicin-induced"/>
  <result pre="M.FragaV. G.de Paula SabinoA.GomesK. B.Troponin as a cardiotoxicity marker in" exact="breast cancer" post="patients receiving anthracycline-based chemotherapy: a narrative reviewBiomedicine &amp;amp; Pharmacotherapy201810798999610.1016/j.biopha.2018.08.03530257411"/>
  <result pre="G.de Paula SabinoA.GomesK. B.Troponin as a cardiotoxicity marker in breast" exact="cancer" post="patients receiving anthracycline-based chemotherapy: a narrative reviewBiomedicine &amp;amp; Pharmacotherapy201810798999610.1016/j.biopha.2018.08.03530257411"/>
  <result pre="maculatus L.Medicine201962p. 5310.3390/medicines602005331052242 80SaleemM.MurtazaI.TaraporeR. S.et al.Lupeol inhibits proliferation of human" exact="prostate cancer" post="cells by targeting beta-catenin signalingCarcinogenesis200930580881710.1093/carcin/bgp04419233958 81WeiL. S.WeeW.SiongJ. Y. F.SyamsumirD."/>
  <result pre="L.Medicine201962p. 5310.3390/medicines602005331052242 80SaleemM.MurtazaI.TaraporeR. S.et al.Lupeol inhibits proliferation of human prostate" exact="cancer" post="cells by targeting beta-catenin signalingCarcinogenesis200930580881710.1093/carcin/bgp04419233958 81WeiL. S.WeeW.SiongJ. Y. F.SyamsumirD."/>
 </snippets>
</snippetsTree>
